Orthofix Medical (OFIX) Depreciation & Amortization (CF) (2010 - 2026)

Orthofix Medical has disclosed Depreciation & Amortization (CF) across 16 years of filings, most recently posting $13.5 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 60.81% year-over-year to $13.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.4 million (down 29.19% YoY) and the FY2025 annual result came in at $77.3 million, up 28.74% from the prior year.
• Depreciation & Amortization (CF) climbed to $13.5 million in Q1 2026, from $13.1 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $34.4 million in Q1 2025 and troughed at $6.5 million in Q2 2022.
• A 5-year average of $13.7 million and a median of $13.3 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) soared 131.67% — and 2026, when it plunged 60.81%.
• Tracing OFIX's Depreciation & Amortization (CF) over 5 years: stood at $7.4 million in 2022, then surged by 88.24% to $14.0 million in 2023, then gained by 14.5% to $16.0 million in 2024, then retreated by 18.23% to $13.1 million in 2025, then grew by 3.17% to $13.5 million in 2026.
• Business Quant data shows OFIX's Depreciation & Amortization (CF) at $13.5 million in Q1 2026, $13.1 million in Q4 2025, and $12.9 million in Q3 2025.